patent.fyi
Applications  /  US 2026/0355077
United States Patent Application Publication

US 2026/0355077 A1

Published
Nov 12, 2026
Filed
Nov 16, 2023
Earliest date on the face
Nov 30, 2022
Classification
A61K 8/19
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Niacinamide in water droplets

What ifWhat if the dispersed water phase contained niacinamide in place of tranexamic acid?
Claim language“tranexamic acid”

Niacinamide dissolves in the water phase before emulsification. The emulsion spreads and releases the dissolved niacinamide onto the skin, where it reduces melanosome transfer from melanocytes to keratinocytes.

1.1Ascorbyl glucoside in water

What ifWhat if the dispersed water phase contained ascorbyl glucoside in place of tranexamic acid?
Claim language“tranexamic acid”

Ascorbyl glucoside dissolves in the water phase before that phase is dispersed into oil. Skin enzymes cleave the glucose group after application, releasing ascorbic acid that reduces oxidized intermediates in melanin formation.

1.2Boron nitride platelets

What ifWhat if boron nitride platelets served as the particulate filler in place of hydrophobized mica?
Claim language“a hydrophobized mica”

Hexagonal boron nitride platelets disperse in the continuous oil phase under shear. Their layered structure provides slip during application, and the platelets align along the skin surface as the film spreads.

1.2Coated alumina platelets

What ifWhat if titanium dioxide coated alumina platelets supplied gloss in place of hydrophobized mica?
Claim language“a hydrophobized mica”

The coated alumina platelets disperse in the continuous oil phase and orient approximately parallel to the skin during spreading. The titanium dioxide coating produces directional reflection through interference at its interfaces.

1.3Silicone elastomer oil gel

What ifWhat if a crosslinked silicone elastomer structured the oil phase in place of an organically modified clay mineral?
Claim language“an organically modified clay mineral”

A dimethicone crosspolymer swells in low-viscosity dimethicone and forms a soft gel in the continuous phase. The gel limits movement of the dispersed water droplets at rest and yields during spreading.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Optical coating for synthetic skin phantoms

A synthetic skin phantom for camera calibration carries a water-in-oil coating with tranexamic acid dissolved in the internal water droplets and 6% by mass hydrophobized mica dispersed in the continuous oil phase. An organically modified clay mineral thickens the oil phase and holds the mica in suspension before application. A drawdown bar spreads the coating across the phantom at a fixed wet thickness, and a camera records its reflectance at fixed illumination and viewing angles.

Component substitution

Hydrophobized talc in the oil phase

Triethoxycaprylylsilane-treated talc replaces the hydrophobized mica at 6% by mass of the finished emulsion. High-shear mixing disperses the organically modified clay mineral in the oil, and subsequent mixing distributes the treated talc throughout that phase. A water-in-oil emulsifier stabilizes the droplets formed when the aqueous tranexamic acid solution enters the oil phase under shear.

Silica gel for oil phase suspension

Hydrophobic fumed silica replaces the organically modified clay mineral as the oil-phase thickener at 1.5% by mass of the finished emulsion. A rotor-stator mixer disperses the silica in oil containing a water-in-oil emulsifier, and a paddle mixer then incorporates 6% by mass hydrophobized mica. The aqueous tranexamic acid solution enters the oil phase under shear, and the silica network develops as mixing slows, restricting mica settling.

Parameter or scale variation

Two mica fractions in one emulsion

The emulsion contains 4% by mass hydrophobized mica with a median particle size of 8 micrometers and 2% by mass hydrophobized mica with a median particle size of 35 micrometers. An organically modified clay mineral is dispersed into the continuous oil phase before the tranexamic acid solution is emulsified into it. A paddle mixer folds both mica fractions into the finished emulsion at low speed to limit platelet breakage.

Combination with existing systems

Airless pump with a metering chamber

An airless piston dispenser holds the water-in-oil emulsion in a cylindrical reservoir beneath a positive-displacement pump. Tranexamic acid resides in the internal water droplets, and the continuous oil phase contains 6% by mass hydrophobized mica and dispersed organically modified clay mineral. Each full pump stroke dispenses 0.2 milliliters through the outlet valve, and the follower piston advances as the metering chamber refills from the reservoir.

Automated or data-driven variant

Load cell control of aqueous dosing

A controller monitors load cells beneath a jacketed mixing vessel containing oil, a water-in-oil emulsifier, an organically modified clay mineral, and enough hydrophobized mica to make up 6% of the finished batch mass. With the rotor-stator mixer running, the controller meters aqueous tranexamic acid solution into the vessel and reduces the feed rate as the measured batch mass approaches its setpoint. At the setpoint, the controller closes the feed valve and continues mixing for a programmed hold time to disperse the aqueous phase as droplets.

Specific version of a part

Dissolved tranexamic acid

Crystalline tranexamic acid dissolves in the aqueous phase at 2% by mass of the finished emulsion. The aqueous phase enters the oil phase under shear and carries the dissolved acid into the dispersed droplets.

Silane treated mica platelets

Mica platelets treated with triethoxycaprylylsilane account for 5% by mass of the finished emulsion. The alkylsilane surface treatment promotes wetting by the continuous oil phase.

Dimethicone coated mica platelets

Dimethicone coated mica platelets account for 8% by mass of the finished emulsion. The platelets are predispersed in a low-viscosity silicone oil before the water phase is emulsified.

Quaternary ammonium modified hectorite

Disteardimonium hectorite disperses in the continuous oil phase under high shear. Propylene carbonate promotes development of a platelet network that increases the yield stress of the oil phase.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0017114 A1
Published
Jan 15, 2009
Filed
Sep 15, 2008
Class
A61K 31/19
Document BUS 2009/0099294 A1
Published
Apr 16, 2009
Filed
Oct 16, 2008
Class
C08K 3/34
Claim 1
Document A
Document B
1.1(A) tranexamic acid;
The tablet contains at least one excipient (defined herein as any substance other than the active, i.e., tranexamic acid) which minimizes or eliminates the adverse gastrointestinal side effects in patients, for example, women dosed with oral tranexamic acid for treatment of menorrhagia.
A · US 2009/0017114 A1 · ¶ 6
1.2(B) 3% to 9% by mass of a hydrophobized mica; and
1.3(C) an organically modified clay mineral.
Organophilic smectite clays are the hydrophobically surface-modified smectite clays, a portion of whose surface is switched from being hydrophilic to hydrophobic, by adsorbing hydrophobic surface-modifying agents onto the platelet surface. The surface-modifier can be a surfactant, for example, an alkyl quaternary ammonium compound, preferably with C8-C22 alkyl chain(s), or a hydrophobic polymer.
B · US 2009/0099294 A1 · ¶ 2

An empty cell means only that no passage was reproduced there.

Statements in these documents
Such side effects, in addition to the cramping, bloating, pain, and other symptoms that may accompany menses, are undesirable, and a formulation of tranexamic acid is needed which will reduce or eliminate these side effects.
A · US 2009/0017114 A1 · ¶ 3
The beneficial effect of this reduced tranexamic acid concentration is to lower the amount of tranexamic acid in the gastric contents so that there are fewer gastric adverse effects with tranexamic acid therapy.
A · US 2009/0017114 A1 · ¶ 4
For example, it might be possible to use organoclays as surface-conditioning agents, as in hair-conditioning and fabric-softening, if they could be dispersed in water-based compositions such as shampoos, conditioners, detergents, and fabric-softeners.
B · US 2009/0099294 A1 · ¶ 4
Unexpectedly, it was found during the research that led to the present invention, that the surface of hydrophobically-modified smectite clays (i.e., organophilic clays) could be modified further using hydrophilic polymers, wherein the hydrophilic surface-modification of the hydrophobically-modified smectite clay with a hydrophilic polymer, would render the organoclays adequately dispersible in water.
B · US 2009/0099294 A1 · ¶ 6
Cite aspatent.fyi, US 2026/0355077 A1, claim 1, first published 2026-11-19T07:53:10-05:00, https://patent.fyi/US20260355077/, SHA-256 61575e284a724b78b52856d555c75641c72813588323e1567e991f51a44fef02
First published
Permanent addresshttps://patent.fyi/US20260355077/
Content fingerprint (SHA-256)61575e284a724b78b52856d555c75641c72813588323e1567e991f51a44fef02
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi